Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses

Vaccine

Volumn 19, Issue 4-5, 2000, Pages 589-594

  Kunisawa, Jun ^a,b   Okudaira, Akiko ^a,b   Tsutusmi, Yasuo ^a   Takahashi, Ichiro ^b   Nakanishi, Tsuyoshi ^a   Kiyono, Hiroshi ^b   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Mucoadhesive polymer dispersed microsphere; Mucosal vaccine

Indexed keywords

DRUG CARRIER; DRUG VEHICLE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROSPHERE; OVALBUMIN; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INTESTINE TRANSIT TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADHESIVES; ANIMAL; ANTIBODY FORMATION; CHICKENS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; MICROSPHERES; OVALBUMIN; POLYMERS; SUPPORT, NON-U.S. GOV'T; VACCINES;

EID: 0034668160     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00094-3     Document Type: Article

References (22)

1. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concept to vaccine development. Vaccine. 10:1992;75-88.
2. Staats H.F., Jackson R.J., Marinaro M., Takahashi I., Kiyono H., McGhee J.R. Mucosal immunity to infection with implications for vaccine development. Current Opinion in Immunology. 6:1994;572-583.
3. O'Hagan DT. Novel delivery systems for oral vaccines. Boca Raton: CRC Press Inc., 1994. 175-205.
4. Takahashi I., Marinaro J., Kiyono H., et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:1996;627-635.
5. Porgador A., Staats H.F., Faiola B., Gilboa E., Palker T.J. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158:1997;834-841.
6. Foster N., Clark M.A., Jepson A., Hirst B.H. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine. 16:1998;536-541.
7. Tabata Y., Inoue Y., Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine. 14:1996;1677-1685.
8. Jones D.H., Corris S., McDonald S., Clegg J.S., Farrar J.H. Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 15:1997;814-817.
9. Zhao Z., Leong K.W. Controlled delivery of antigens and adjuvants in vaccine development. J. Pharm. Sci. 85:1996;1261-1270.
10. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology. 81:1994;661-667.
11. Heritage P.L., Brook M.A., Underdown B.J., McDermott M.R. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes. Immunology. 93:1998;249-256.
12. Akiyama Y., Nagahara N., Kashihara T., Hirai S., Toguchi H. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm. Res. 12:1995;397-405.
13. Akiyama Y., Nagahara N., Nara N., et al. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin compounds with limited gastrointestinal absorption sites. J. Pharm. Pharmacol. 50:1998;159-166.
14. Estrada A., McDermott M.R., Underdown B.J., Snider D.P. Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Vaccine. 13:1995;901-907.
15. Jain S.L., Michael J.G. The influence of antigen digestion on orally induced immunity and tolerance. Adv. Exp. Med. Biol. 371:1995;1245-1250.
16. Yamamoto S., Takeda Y., Yamamoto M., et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1997;1203-1210.
17. Yamamoto S., Kiyono H., Yamamoto M., et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA. 94:1997;5267-5272.
18. Cusimato A.G., Becker C.H. Spray-congealed formulations of sulffaethylthiadiazole (SETD) and waxes for prolonged release medication. J. Pharm. Sci. 57:1968;1104-1112.
19. Das S.K., Gupta B.K. Optimization of controlled release through micropelletization. Drug. Dev. Ind. Pharm. 14:1988;1673-1697.
20. Ishino R., Yoshino H., Hirakawa Y., Noda K. Influence of internal structure on kinetics of drug release from wax matrix tablets. Chem. Pharm. Bull. 38:1990;3440-3445.
21. Akiyama Y., Yoshioka M., Horibe H., Hirai S., Kitamori N., Toguchi H. Novel oral controlled-release microspheres using polyglycerol esters of fatty acids. Journal of Controlled Release. 26:1993;1-10.
22. Michael J.G. The role of digestive enzyme in orally induced immune tolerance. Immunological Investigation. 18:1989;1049-1054.